Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch

July 15, 2026 9:00 AM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today it has received approval from the European Notified Body to manufacture GelrinC® using its next-generation solvent-free manufacturing process.The approval comes as Regentis prepares for the commercial launch of GelrinC® in Europe, enabling the Company to manufacture...

Read more

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

July 15, 2026 8:30 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.As part of the segment, Mr. Berman discussed the Company's recent news announcing the issuance of the first U.S. Patent covering the company's enVVe system, further expanding its intellectual property portfolio and laying the...

Read more

Biovica Receives Ninth Work Order From a Leading Global Pharmaceutical Customer

July 14, 2026 3:10 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announced that it has received a new work order from a current customer, one of the world's leading pharmaceutical companies with a strong oncology pipeline. This marks the ninth work order received from the same customer, further strengthening the ongoing collaboration.The work order covers DiviTum® TKa testing...

Read more

High-Sensitivity Detection Breaks Technical Barriers! Cloud-Clone’s Small Molecule Hormone ELISA Kits Elevate Global Biomedical Research Standards News Lead

July 13, 2026 3:00 PM

Hormones act as invisible signaling messengers regulating nearly all biological activities, playing irreplaceable roles in inflammation, reproductive development, tumor microenvironment research, neuroscience and other core life science fields. However, small-molecule hormones face inherent detection bottlenecks: highly similar chemical structures, lack of dual binding epitopes required for conventional immunoassays, ultra-low concentrations in...

Read more

Synexis, LLC and Penn Veterinary Supply Collaborate to offer DHP(R) Technology Across Animal Health Facilities Nationwide

July 13, 2026 1:35 PM

Synexis®, LLC, the leader in touchless, continuous pathogen control technology, today announced a strategic collaboration with Penn Veterinary Supply to expand access to Synexis DHP® technology for veterinary and animal health professionals nationwide.The Synexis and Penn Veterinary Supply collaboration reflects a growing shift across veterinary medicine and animal care toward more proactive, science-based biosecurity strategies designed to...

Read more

OSR Health, A Message From the CEO

July 13, 2026 12:37 PM

OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from Chief Executive Officer to shareholders.To Every OSR Health Shareholder:OSR Health is at an inflection point - one that I believe will be looked back upon as the moment this company's underlying value began to be recognized by the broader market. Before that recognition arrives, I want to speak to the shareholders who have been here all along.You chose to believe in what we...

Read more

Bora Biologics Expands U.S. Commercial Manufacturing Platform with Addition of Rockville Site

July 13, 2026 6:00 AM

Bora Biologics, a U.S.-based biologics CDMO engineered for licensed supply, today announced the expansion of its U.S. drug substance manufacturing platform through the addition of the Rockville, Maryland site. The addition strengthens the company's U.S.-anchored BioSecure commercial platform and reinforces its long-term investment in domestic biologics manufacturing.With the addition of Rockville, Bora Biologics scales its total offering of...

Read more

Faron Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab

July 13, 2026 2:10 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today provides an update on its portfolio of Investigator-Initiated Trials (IITs) evaluating bexmarilimab, its wholly owned anti-Clever-1 immunotherapy, in multiple oncology indications. The update covers five IITs in solid tumors and hematological...

Read more

MPI Approval and IXOM Partnership Signal Growing Momentum for Continuous Pathogen Control for New Zealand's Food Industry

July 9, 2026 6:50 PM

Synexis®, LLC, the leader in touchless, continuous pathogen control technology, has announced a strategic collaboration with IXOM, one of Australia and New Zealand's most trusted providers of cleaning and sanitation, water treatment and industrial chemical solutions, following approval from New Zealand's Ministry for Primary Industries (MPI) for the use of Synexis DHP® technology in dairy and non-dairy processing facilities.The collaboration...

Read more

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

July 9, 2026 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will showcase its artificial intelligence portfolio across seven scientific presentations at the Alzheimer's Association International Conference (AAIC) 2026, taking place July 12-15 in London. IGC Pharma is building computational infrastructure designed to accelerate data...

Read more

BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies

July 8, 2026 8:00 AM

BioStem Technologies, Inc. (OTCID:BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the United States Patent and Trademark Office (USPTO) has issued four U.S. design patents covering the Company's proprietary fenestrated human placental allograft technologies.The newly issued patents strengthen BioStem's intellectual...

Read more

Synexis Releases "The Illusion of Clean," Examining What Happens Between Cleaning Events in Healthcare

July 7, 2026 1:09 PM

Healthcare has spent decades advancing some of the most sophisticated cleaning, disinfection, and infection prevention protocols in the world.Those practices remain essential. But the environments they protect never stand still.That tension is at the center of "The Illusion of Clean: Why Healthcare Is Missing a Critical Layer in Pathogen Control," a new thought leadership article released today by Synexis®, the leader in DHP® pathogen control...

Read more

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

July 7, 2026 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Chief Executive Officer Ram Mukunda and Principal Financial Officer Claudia Grimaldi have purchased an aggregate of 4,274,853 shares of IGC common stock directly from the Company at $0.27 per share. The shares were purchased through the cancellation of approximately $1.15...

Read more

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

July 7, 2026 8:29 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced the issuance of U.S. Patent No. 12,575,932, further expanding its intellectual property portfolio supporting its enVVe® transcatheter replacement venous valve system for the treatment of venous disease.The issued patent covers key components of the enVVe system, including the enVVe valve, valve support frame, crimping system, and delivery system, as...

Read more

Correction: Biovica appoints Maria Ekdahl as new Chief Financial Officer

July 7, 2026 8:07 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica International AB today announced the appointment of Maria Ekdahl as Chief Financial Officer (CFO). Ekdahl brings more than 20 years of senior finance leadership experience, including her current role as CFO of Nasdaq Stockholm-listed pharmaceutical company, Infant Bacterial Therapeutics AB (IBT), and will join Biovica on October 14, 2026.Ekdahl has broad experience across...

Read more

Absentia Labs' Digital Liver Model Becomes First AI Drug Development Tool Accepted Into FDA Qualification Program

July 7, 2026 8:06 AM

Absentia Labs, a biotech startup building comprehensive AI models of human biology, announces the acceptance of its Digital Liver Model for predicting Drug-Induced Liver Injury (DILI) into the U.S. Food and Drug Administration's (FDA) Drug Development Tool Qualification Program."Much of the conversation around AI in pharmaceuticals has focused on drug discovery and finding promising new molecules faster," said Farhan Khodaee, PhD, CEO and...

Read more

Biovica Appoints Maria Ekdahl as New Chief Financial Officer

July 7, 2026 7:15 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica International AB today announced the appointment of Maria Ekdahl as Chief Financial Officer (CFO). Ekdahl brings more than 20 years of senior finance leadership experience, including her current role as CFO of Nasdaq Stockholm-listed pharmaceutical company, Infant Bacterial Therapeutics AB (IBT), and will join Biovica on October 14, 2026.Ekdahl has broad experience across...

Read more

Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026

July 7, 2026 6:00 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F), a clinical-stage biopharmaceutical company advancing high-potential drug candidates for diseases with significant unmet medical needs through a disciplined pharmaceutical development platform and focused subsidiary companies, today announced that it has filed its Notice of Annual General and Special Meeting and Management Information Circular (the "Circular") for its upcoming Annual General...

Read more

Biovica Expands Master Services Agreement with a Current Customer, a Leading Global Pharmaceutical Company, to Support Next-Generation Oncology Development

July 7, 2026 4:15 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announces an expanded Master Services Agreement with a current customer, one of the world's leading pharmaceutical companies, which has a broad and active oncology pipeline. Under the agreement, Biovica will provide DiviTum® TKa testing services for oncology development programs.The agreement establishes an...

Read more

Vicore Pharma to Participate in the Leerink Therapeutics Forum

July 7, 2026 2:20 AM

Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Leerink Therapeutics Forum.Location: Boston Harbor Hotel, Boston, Mass.Format: 1×1 meetingsDate: Tuesday, July 14, 2026Participant: Ahmed Mousa, CEOFor more information, please...

Read more